6 Key Takeaways
-
1
Several oncology drugs were FDA approved in the last year.
-
2
Enfortumab vedotin shows a 44% response rate in advanced bladder cancer.
-
3
Fam-trastuzumab deruxtecan had a 61% response rate in HER2+ breast cancer.
-
4
Tucatinib is effective for HER2+ breast cancer with brain metastases.
-
5
Safety assessments revealed significant adverse effects for some treatments.
-
6
Immunotherapy approvals expanded, including pembrolizumab and ipilimumab combinations.
In the past year, the FDA has approved several oncology drugs for solid tumors, as highlighted by Dr. Kirollos S. Hanna from M Health Fairview during JADPRO Live Virtual 2020. Notable approvals include enfortumab vedotin for advanced bladder cancer, fam-trastuzumab deruxtecan for HER2-positive breast cancer, and tucatinib for HER2-positive metastatic breast cancer with notable efficacy in patients with brain metastases. Safety profiles were examined, revealing common adverse effects; some treatments also posed significant risks of serious toxicities. Dr. Hanna also covered expanded indications for immunotherapy drugs.
Listen Tab content
